|
WO2006052767A2
|
|
Compositions and methods for stabilizing liposomal camptothecin formulations
|
|
CA2576222A1
|
|
Compositions and methods for treating lymphoma
|
|
AU2005251691A1
|
|
Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
|
|
EP1675614A2
|
|
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
WO2005011698A1
|
|
Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
|
|
WO03094828A2
|
|
Cancer vaccines and methods of using the same
|
|
WO03094829A2
|
|
Pathogen vaccines and methods for using the same
|
|
US2004013649A1
|
|
Cancer vaccines and methods of using the same
|
|
US2004009943A1
|
|
Pathogen vaccines and methods for using the same
|
|
US2004009944A1
|
|
Methylated immunostimulatory oligonucleotides and methods of using the same
|
|
WO02089772A1
|
|
Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
|
|
AU2773902A
|
|
Polyamide oligomers
|
|
CA2426047A1
|
|
Therapeutic oligonucleotides of reduced toxicity
|
|
AU7038501A
|
|
Liposomal antineoplastic drugs and uses thereof
|
|
AU7166700A
|
|
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
CA2382611A1
|
|
Compositions for stimulating cytokine secretion and inducing an immune response
|
|
US7094423B1
|
|
Methods for preparation of lipid-encapsulated therapeutic agents
|
|
AU6256100A
|
|
Methods and apparatus for preparation of lipid vesicles
|
|
IL145720D0
|
|
Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids
|
|
US6723338B1
|
|
Compositions and methods for treating lymphoma
|
